恩必普治疗急性缺血性脑卒中的疗效及其对患者血清hs-CRP水平的影响

目的 观察恩必普治疗急性缺血性脑卒中的疗效,探讨其对患者血清超敏C反应蛋白(hs-CRP)水平的影响.方法 选择我院内科于2015年8月至2016年8月期间收治的56例急性缺血性脑卒中患者为研究对象,根据随机数表法随机分为观察组(n=28)和对照组(n=28),对照组予抗血小板等常规治疗,观察组联合应用口服恩必普(丁苯酞软胶囊),14 d为一个疗程.采用美国国立卫生研究院卒中量表(NIHSS)评价两组患者治疗前后的神经功能缺损情况,并比较其血清hs-CRP水平.结果 观察组与对照组治疗后NIHSS评分分别为(5.81±1.94)分和(7.33±2.38)分,血清hs-CRP分别为(6.69±1.54)mg/L和(8.96±1.98)mg/L,均明显低于治疗前的(12.78±3.51)分、(12.64±4.86)分和(12.69±3.94)mg/L、(12.84±3.58)mg/L,差异均有统计学意义(P<0.05).结论 恩必普治疗急性缺血性脑卒中可以有效降低患者血清hs-CRP水平,改善患者的神经功能缺损,提高临床疗效.

Curative effect of DL-3-n-butylphthalide in the treatment of acute ischemic stroke and its effect on serum hs-CRP.

Objective To investigate the effect DL-3-n-butylphthalide (NBP) in the treatment of acute isch-emic stroke (AIS) and its effect on serum high-sensitivity C-reactive protein (hs-CRP). Methods A total of 56 cases of patients with AIS, who admitted to Department of Neurology of our hospital from August 2015 to August 2016, were se-lected as the research objects and divided into the observation group (n=28) and the control group (n=28) according to randomly number table. The control group was treated with antiplatelet and other conventional treatment, and the ob-servation group was treated with additional oral NBP. All the patients were treated for 14 d. The neurological deficits before and after the treatment in the two groups were evaluated by National Institutes of Health Stroke Scale (NIHSS), and the serum hs-CRP levels of the two groups were compared. Results The NIHSS and the levels of hs-CRP after treatment in the observation group and the control group were respectively (5.81±1.94), (7.33±2.38), (6.69±1.54) mg/L, (8.96±1.98) mg/L, which were significantly lower than (12.78±3.51), (12.64±4.86), (12.69 ±3.94) mg/L, (12.84±3.58) mg/L before treatment (P<0.05). Conclusion NBP can effectively reduce the level of serum hs-CRP in the treatment of AIS, and improve the neurological function and clinical efficacy.